Why the study?
Does intravenous glibenclamide alter coronary blood flow in normal and post-stenotic coronary arteries in patients with high-grade coronary stenosis?
Does intravenous glibenclamide alter coronary blood flow in normal and post-stenotic coronary arteries in patients with high-grade coronary stenosis?
Therapeutic doses of intravenous glibenclamide do not compromise coronary blood flow or vasodilatation in normal or post-stenotic coronary arteries at rest.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Curtis et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: